FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Pathogens (Basel, Switzerland)2021; 10(9); doi: 10.3390/pathogens10091092

Vesicular Stomatitis Virus: From Agricultural Pathogen to Vaccine Vector.

Abstract: Vesicular stomatitis virus (VSV), which belongs to the Vesiculovirus genus of the family Rhabdoviridae, is a well studied livestock pathogen and prototypic non-segmented, negative-sense RNA virus. Although VSV is responsible for causing economically significant outbreaks of vesicular stomatitis in cattle, horses, and swine, the virus also represents a valuable research tool for molecular biologists and virologists. Indeed, the establishment of a reverse genetics system for the recovery of infectious VSV from cDNA transformed the utility of this virus and paved the way for its use as a vaccine vector. A highly effective VSV-based vaccine against Ebola virus recently received clinical approval, and many other VSV-based vaccines have been developed, particularly for high-consequence viruses. This review seeks to provide a holistic but concise overview of VSV, covering the virus's ascension from perennial agricultural scourge to promising medical countermeasure, with a particular focus on vaccines.
Get Full Text
Publication Date: 2021-08-27 PubMed ID: 34578125PubMed Central: PMC8470541DOI: 10.3390/pathogens10091092Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article provides an overview of the Vesicular stomatitis virus (VSV), highlighting its transition from being a harmful agricultural pathogen to a potentially beneficial vaccine vector, especially in the development of vaccines against high-consequence viruses like Ebola.

Vesicular Stomatitis Virus: An Overview

  • The Vesicular stomatitis virus (VSV) belongs to the Rhabdoviridae family. It is a negative-sense RNA virus that has been researched extensively due to its impact on livestock.
  • VSV is known to cause significant outbreaks of vesicular stomatitis in agricultural animals like cattle, horses, and swine. These outbreaks often result in substantial economic losses.

VSV as a Research Tool

  • Despite its harmfulness to livestock, VSV has proven to be a valuable tool for molecular biologists and virologists.
  • The establishment of a reverse genetics system for the recovery of VSV from cDNA (complementary DNA) has expanded the usefulness of the virus, leading to developments in its use as a vaccine vector.

Use of VSV as a Vaccine Vector

  • A vaccine vector is a virus or bacterium used to transport a DNA sequence into a human cell. The feasibility of VSV as a vaccine vector became evident when it was effectively used to develop a vaccine against Ebola virus, which eventually gained clinical approval.
  • Besides Ebola, VSV-based vaccines have been developed for several other high-consequence viruses, demonstrating the potential of VSV for medical applications.

Conclusion and Future Directions

  • This review aims to provide a comprehensive yet concise overview of VSV. It emphasizes the virus’s transition from an agricultural pathogen to a promising medical tool.
  • With a particular focus on vaccines, the review highlights how VSV has transformed from a recurring issue in agriculture to a significant contributor to medical breakthroughs.
  • In the future, there is potential for more life-saving vaccines to be developed using VSV as a vector, particularly against viruses causing severe diseases.

Cite This Article

APA
Liu G, Cao W, Salawudeen A, Zhu W, Emeterio K, Safronetz D, Banadyga L. (2021). Vesicular Stomatitis Virus: From Agricultural Pathogen to Vaccine Vector. Pathogens, 10(9). https://doi.org/10.3390/pathogens10091092

Publication

Pathogens (Basel, Switzerland)
ISSN: 2076-0817
NlmUniqueID: 101596317
Country: Switzerland
Language: English
Volume: 10
Issue: 9

Researcher Affiliations

Liu, Guodong
  • Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada.
Cao, Wenguang
  • Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada.
Salawudeen, Abdjeleel
  • Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.
Zhu, Wenjun
  • Canadian Food Inspection Agency, National Centre for Foreign Animal Disease, Winnipeg, MB R3E 3M4, Canada.
Emeterio, Karla
  • Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada.
  • Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.
Safronetz, David
  • Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada.
  • Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.
Banadyga, Logan
  • Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada.

Conflict of Interest Statement

The authors declare no conflict of interest.

References

This article includes 134 references
  1. Walker P.J., Blasdell K.R., Calisher C.H., Dietzgen R.G., Kondo H., Kurath G., Longdon B., Stone D.M., Tesh R.B., Tordo N.. ICTV Virus Taxonomy Profile: Rhabdoviridae. J. Gen. Virol. 2018;99:447–448.
    doi: 10.1099/jgv.0.001020pubmed: 29465028google scholar: lookup
  2. Walker P.J., Firth C., Widen S.G., Blasdell K.R., Guzman H., Wood T.G., Paradkar P.N., Holmes E.C., Tesh R.B., Vasilakis N.. Evolution of Genome Size and Complexity in the Rhabdoviridae. PLoS Pathog. 2015;11:e1004664.
    doi: 10.1371/journal.ppat.1004664pmc: PMC4334499pubmed: 25679389google scholar: lookup
  3. Rodriguez L.L., Pauszek S.J., Bunch T.A., Schumann K.R.. Full-length genome analysis of natural isolates of vesicular stomatitis virus (Indiana 1 serotype) from North, Central and South America. J. Gen. Virol. 2002;83:2475–2483.
    doi: 10.1099/0022-1317-83-10-2475pubmed: 12237430google scholar: lookup
  4. Peluso R.W., Richardson J.C., Talon J., Lock M.. Identification of a set of proteins (C′ and C) encoded by the bicistronic P gene of the Indiana serotype of vesicular stomatitis virus and analysis of their effect on transcription by the viral RNA polymerase. Virology 1996;218:335–342.
    doi: 10.1006/viro.1996.0202pubmed: 8610460google scholar: lookup
  5. Spiropoulou C.F., Nichol S.T.. A small highly basic protein is encoded in overlapping frame within the P gene of vesicular stomatitis virus. J. Virol. 1993;67:3103–3110.
    doi: 10.1128/jvi.67.6.3103-3110.1993pmc: PMC237647pubmed: 8388490google scholar: lookup
  6. Ge P., Tsao J., Schein S., Green T.J., Luo M., Zhou Z.H.. Cryo-EM model of the bullet-shaped vesicular stomatitis virus. Science 2010;327:689–693.
    doi: 10.1126/science.1181766pmc: PMC2892700pubmed: 20133572google scholar: lookup
  7. Riedel C., Hennrich A.A., Conzelmann K.K.. Components and Architecture of the Rhabdovirus Ribonucleoprotein Complex. Viruses 2020;12:959.
    doi: 10.3390/v12090959pmc: PMC7552012pubmed: 32872471google scholar: lookup
  8. Thomas D., Newcomb W.W., Brown J.C., Wall J.S., Hainfeld J.F., Trus B.L., Steven A.C.. Mass and molecular composition of vesicular stomatitis virus: A scanning transmission electron microscopy analysis. J. Virol. 1985;54:598–607.
    doi: 10.1128/jvi.54.2.598-607.1985pmc: PMC254833pubmed: 2985822google scholar: lookup
  9. Green T.J., Zhang X., Wartz G.W., Luo M.. Structure of the vesicular stomatitis virus nucleoprotein-RNA complex. Science 2006;313:357–360.
    doi: 10.1126/science.1126953pubmed: 16778022google scholar: lookup
  10. Liang B., Li Z., Jenni S., Rahmeh A.A., Morin B.M., Grant T., Grigorieff N., Harrison S.C., Whelan S.P.J.. Structure of the L Protein of Vesicular Stomatitis Virus from Electron Cryomicroscopy. Cell 2015;162:314–327.
    doi: 10.1016/j.cell.2015.06.018pmc: PMC4557768pubmed: 26144317google scholar: lookup
  11. Gould J.R., Qiu S., Shang Q., Ogino T., Prevelige P.E., Petit C.M., Green T.J.. The Connector Domain of Vesicular Stomatitis Virus Large Protein Interacts with the Viral Phosphoprotein. J. Virol. 2020;94:e01729-19.
    doi: 10.1128/JVI.01729-19pmc: PMC7158708pubmed: 31896592google scholar: lookup
  12. Leyrat C., Yabukarski F., Tarbouriech N., Ribeiro E.A., Jensen M.R., Blackledge M., Ruigrok R.W.H., Jamin M.. Structure of the vesicular stomatitis virus n 0-p complex. PLoS Pathog. 2011;7:e1002248.
    doi: 10.1371/journal.ppat.1002248pmc: PMC3178552pubmed: 21960769google scholar: lookup
  13. Ding H., Green T.J., Lu S., Luo M.. Crystal Structure of the Oligomerization Domain of the Phosphoprotein of Vesicular Stomatitis Virus. J. Virol. 2006;80:2808–2814.
    doi: 10.1128/JVI.80.6.2808-2814.2006pmc: PMC1395454pubmed: 16501089google scholar: lookup
  14. Green T.J., Luo M.. Structure of the vesicular stomatitis virus nucleocapsid in complex with the nucleocapsid-binding domain of the small polymerase cofactor, P. Proc. Natl. Acad. Sci. USA 2009;106:11713–11718.
    doi: 10.1073/pnas.0903228106pmc: PMC2710649pubmed: 19571006google scholar: lookup
  15. Gaudier M., Gaudin Y., Knossow M.. Crystal structure of vesicular stomatitis virus matrix protein. EMBO J. 2002;21:2886–2892.
    doi: 10.1093/emboj/cdf284pmc: PMC126044pubmed: 12065402google scholar: lookup
  16. Newcomb W.W., Brown J.C.. Role of the vesicular stomatitis virus matrix protein in maintaining the viral nucleocapsid in the condensed form found in native virions. J. Virol. 1981;39:295–299.
    doi: 10.1128/jvi.39.1.295-299.1981pmc: PMC171289pubmed: 6268817google scholar: lookup
  17. Roche S., Rey F.A., Gaudin Y., Bressanelli S.. Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G. Science 2007;315:843–848.
    doi: 10.1126/science.1135710pubmed: 17289996google scholar: lookup
  18. Roche S., Bressanelli S., Rey F.A., Gaudin Y.. Crystal structure of the low-pH form of the vesicular stomatitis virus glycoprotein G. Science 2006;313:187–191.
    doi: 10.1126/science.1127683pubmed: 16840692google scholar: lookup
  19. Banerjee A.K., Barik S.. Gene expression of vesicular stomatitis virus genome RNA. Virology 1992;188:417–428.
    doi: 10.1016/0042-6822(92)90495-Bpubmed: 1316668google scholar: lookup
  20. Lyles D.S., Kuzmin I.V., Rupprecht C.E.. Rhabdoviridae. 2013. In: Knipe D.M., Howley P.M., editors. Fields Virology. Wolters Kluwer; Philadelphia, PA, USA: pp. 885–922.
  21. Finkelshtein D., Werman A., Novick D., Barak S., Rubinstein M.. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc. Natl. Acad. Sci. USA 2013;110:7306–7311.
    doi: 10.1073/pnas.1214441110pmc: PMC3645523pubmed: 23589850google scholar: lookup
  22. Nikolic J., Belot L., Raux H., Legrand P., Gaudin Y., Albertini A.A.. Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein. Nat. Commun. 2018;9:1029.
    doi: 10.1038/s41467-018-03432-4pmc: PMC5847621pubmed: 29531262google scholar: lookup
  23. Belot L., Albertini A., Gaudin Y.. Structural and cellular biology of rhabdovirus entry. Adv. Virus Res. 2019;104:147–183.
    doi: 10.1016/bs.aivir.2019.05.003pubmed: 31439148google scholar: lookup
  24. Mire C.E., White J.M., Whitt M.A.. A spatio-temporal analysis of matrix protein and nucleocapsid trafficking during vesicular stomatitis virus uncoating. PLoS Pathog. 2010;6:e1000994.
    doi: 10.1371/journal.ppat.1000994pmc: PMC2904772pubmed: 20657818google scholar: lookup
  25. Barr J.N., Whelan S.P.J., Wertz G.W.. Transcriptional control of the RNA-dependent RNA polymerase of vesicular stomatitis virus. Biochim. Biophys. Acta-Gene Struct. Expr. 2002;1577:337–353.
    doi: 10.1016/S0167-4781(02)00462-1pubmed: 12213662google scholar: lookup
  26. Arnheiter H., Davis N.L., Wertz G., Schubert M., Lazzarini R.A.. Role of the nucleocapsid protein in regulating vesicular stomatitis virus RNA synthesis. Cell 1985;41:259–267.
    doi: 10.1016/0092-8674(85)90079-0pubmed: 2986844google scholar: lookup
  27. Lyles D.S.. Assembly and Budding of Negative-Strand RNA Viruses. Adv. Virus Res. 2013;85:57–90.
    doi: 10.1016/B978-0-12-408116-1.00003-3pubmed: 23439024google scholar: lookup
  28. Fine S.M.. Vesicular Stomatitis Virus and Related Vesiculoviruses. 2014. In: Bennett J.E., Dolin R., Blaser M.J., editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. Volume 2. Elsevier; Philadelphia, PA, USA: pp. 1981–1983.e1.
  29. Letchworth G.J., Rodriguez L.L., Barrera J.D.C.. Vesicular stomatitis. Vet. J. 1999;157:239–260.
    doi: 10.1053/tvjl.1998.0303pubmed: 10328837google scholar: lookup
  30. Teidebold T.C., Mather C.S., Merrillat L.A.. Gangrenous glossitis of horses; Proceedings of the 20th Annual Meeting of the United States Live Stock Sanitary Association; Chicago, IL, USA. 5–7 December 1916; pp. 29–42.
  31. Hanson R.P.. Discussion of the natural history of vesicular stomatitis. Am. J. Epidemiol. 1968;87:264–266.
    doi: 10.1093/oxfordjournals.aje.a120815pubmed: 4296725google scholar: lookup
  32. Cotton W.E.. Vesicular stomatitis. Vet. Med. 1927;22:169–175.
  33. Rozo-Lopez P., Drolet B.S., Londoño-Renteria B.. Vesicular stomatitis virus transmission: A comparison of incriminated vectors. Insects 2018;9:190.
    doi: 10.3390/insects9040190pmc: PMC6315612pubmed: 30544935google scholar: lookup
  34. Corn J.L., Comer J.A., Erickson G.A., Nettles V.F.. Isolation of vesicular stomatitis virus New Jersey serotype from phlebotomine sand flies in Georgia. Am. J. Trop. Med. Hyg. 1990;42:476–482.
    doi: 10.4269/ajtmh.1990.42.476pubmed: 1971158google scholar: lookup
  35. Fields B.N., Hawkins K.. Human Infection with the Virus of Vesicular Stomatitis during an Epizootic. N. Engl. J. Med. 1967;277:989–994.
    doi: 10.1056/NEJM196711092771901pubmed: 4293856google scholar: lookup
  36. Munis A.M., Bentley E.M., Takeuchi Y.. A tool with many applications: Vesicular stomatitis virus in research and medicine. Expert Opin. Biol. Ther. 2020;20:1187–1201.
    doi: 10.1080/14712598.2020.1787981pubmed: 32602788google scholar: lookup
  37. Schnell M.J., Mebatsion T., Conzelmann K.K.. Infectious rabies viruses from cloned cDNA. EMBO J. 1994;13:4195–4203.
    doi: 10.1002/j.1460-2075.1994.tb06739.xpmc: PMC395346pubmed: 7925265google scholar: lookup
  38. Whelan S.P.J., Ball L.A., Barr J.N., Wertz G.T.W.. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc. Natl. Acad. Sci. USA 1995;92:8388–8392.
    doi: 10.1073/pnas.92.18.8388pmc: PMC41162pubmed: 7667300google scholar: lookup
  39. Lawson N.D., Stillman E.A., Whitt M.A., Rose J.K.. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. USA 1995;92:4477–4481.
    doi: 10.1073/pnas.92.10.4477pmc: PMC41967pubmed: 7753828google scholar: lookup
  40. Pfaller C.K., Cattaneo R., Schnell M.J.. Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics. Virology 2015;479–480:331–344.
    doi: 10.1016/j.virol.2015.01.029pmc: PMC4557643pubmed: 25702088google scholar: lookup
  41. Le Mercier P., Jacob Y., Tanner K., Tordo N.. A Novel Expression Cassette of Lyssavirus Shows that the Distantly Related Mokola Virus Can Rescue a Defective Rabies Virus Genome. J. Virol. 2002;76:2024–2027.
    doi: 10.1128/JVI.76.4.2024-2027.2002pmc: PMC135871pubmed: 11799201google scholar: lookup
  42. McGettigan J.P., Naper K., Orenstein J., Koser M., McKenna P.M., Schnell M.J.. Functional Human Immunodeficiency Virus Type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and Env Expressed from a Single Rhabdovirus-Based Vaccine Vector Genome. J. Virol. 2003;77:10889–10899.
    doi: 10.1128/JVI.77.20.10889-10899.2003pmc: PMC224996pubmed: 14512539google scholar: lookup
  43. Buchholz U.J., Finke S., Conzelmann K.-K.. Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA: BRSV NS2 Is Not Essential for Virus Replication in Tissue Culture, and the Human RSV Leader Region Acts as a Functional BRSV Genome Promoter. J. Virol. 1999;73:251–259.
    doi: 10.1128/JVI.73.1.251-259.1999pmc: PMC103829pubmed: 9847328google scholar: lookup
  44. Harty R.N., Brown M.E., Hayes F.P., Wright N.T., Schnell M.J.. Vaccinia virus-free recovery of vesicular stomatitis virus. J. Mol. Microbiol. Biotechnol. 2001;3:513–517.
    pubmed: 11545270
  45. Inoue K.I., Shoji Y., Kurane I., Iijima T., Sakai T., Morimoto K.. An improved method for recovering rabies virus from cloned cDNA. J. Virol. Methods 2003;107:229–236.
    doi: 10.1016/S0166-0934(02)00249-5pubmed: 12505638google scholar: lookup
  46. Haglund K., Forman J., Kräusslich H.G., Rose J.K.. Expression of human immunodeficiency virus type 1 gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: High-level production of virus-like particles containing HIV envelope. Virology 2000;268:112–121.
    doi: 10.1006/viro.1999.0120pubmed: 10683333google scholar: lookup
  47. Whitt M.A.. Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J. Virol. Methods 2010;169:365–374.
    doi: 10.1016/j.jviromet.2010.08.006pmc: PMC2956192pubmed: 20709108google scholar: lookup
  48. Gutierrez-Guerrero A., Cosset F.L., Verhoeyen E.. Lentiviral Vector Pseudotypes: Precious Tools to Improve Gene Modification of Hematopoietic Cells for Research and Gene Therapy. Viruses 2020;12:1016.
    doi: 10.3390/v12091016pmc: PMC7551254pubmed: 32933033google scholar: lookup
  49. Garbutt M., Liebscher R., Wahl-Jensen V., Jones S., Möller P., Wagner R., Volchkov V., Klenk H.-D., Feldmann H., Ströher U.. Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses. J. Virol. 2004;78:5458–5465.
    doi: 10.1128/JVI.78.10.5458-5465.2004pmc: PMC400370pubmed: 15113924google scholar: lookup
  50. Konduru K., Shurtleff A.C., Bradfute S.B., Nakamura S., Bavari S., Kaplan G.. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge. PLoS ONE 2016;11:e0162446.
    doi: 10.1371/journal.pone.0162446pmc: PMC5021345pubmed: 27622456google scholar: lookup
  51. DeBuysscher B.L., Scott D., Marzi A., Prescott J., Feldmann H.. Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins. Vaccine 2014;32:2637–2644.
    doi: 10.1016/j.vaccine.2014.02.087pmc: PMC4829066pubmed: 24631094google scholar: lookup
  52. Takada A., Robison C., Goto H., Sanchez A., Murti K.G., Whitt M.A., Kawaoka Y.. A system for functional analysis of Ebola virus glycoprotein. Proc. Natl. Acad. Sci. USA 1997;94:14764–14769.
    doi: 10.1073/pnas.94.26.14764pmc: PMC25111pubmed: 9405687google scholar: lookup
  53. Chattopadhyay A., Rose J.K.. Complementing Defective Viruses That Express Separate Paramyxovirus Glycoproteins Provide a New Vaccine Vector Approach. J. Virol. 2011;85:2004–2011.
    doi: 10.1128/JVI.01852-10pmc: PMC3067786pubmed: 21177820google scholar: lookup
  54. Ito H., Watanabe S., Sanchez A., Whitt M.A., Kawaoka Y.. Mutational Analysis of the Putative Fusion Domain of Ebola Virus Glycoprotein. J. Virol. 1999;73:8907–8912.
    doi: 10.1128/JVI.73.10.8907-8912.1999pmc: PMC112919pubmed: 10482652google scholar: lookup
  55. Ito H., Watanabe S., Takada A., Kawaoka Y.. Ebola Virus Glycoprotein: Proteolytic Processing, Acylation, Cell Tropism, and Detection of Neutralizing Antibodies. J. Virol. 2001;75:1576–1580.
    doi: 10.1128/JVI.75.3.1576-1580.2001pmc: PMC114066pubmed: 11152533google scholar: lookup
  56. Schnell M.J., Buonocore L., Whitt M.A., Rose J.K.. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J. Virol. 1996;70:2318–2323.
    doi: 10.1128/jvi.70.4.2318-2323.1996pmc: PMC190073pubmed: 8642658google scholar: lookup
  57. Jones S.M., Feldmann H., Ströher U., Geisbert J.B., Fernando L., Grolla A., Klenk H.D., Sullivan N.J., Volchkov V.E., Fritz E.A.. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 2005;11:786–790.
    doi: 10.1038/nm1258pubmed: 15937495google scholar: lookup
  58. Jones S.M., Ströher U., Fernando L., Qiu X., Alimonti J., Melito P., Bray M., Klenk H.D., Feldmann H.. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J. Infect. Dis. 2007;196:S404–S412.
    doi: 10.1086/520591pubmed: 17940977google scholar: lookup
  59. Qiu X., Fernando L., Alimonti J.B., Melito P.L., Feldmann F., Dick D., Ströher U., Feldmann H., Jones S.M.. Mucosal immunization of cynomolgus macaques with the VSVΔG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS ONE 2009;4:e5547.
    doi: 10.1371/journal.pone.0005547pmc: PMC2678264pubmed: 19440245google scholar: lookup
  60. Feldmann H., Jones S.M., Daddario-DiCaprio K.M., Geisbert J.B., Ströher U., Grolla A., Bray M., Fritz E.A., Fernando L., Feldmann F.. Effective post-exposure treatment of ebola infection. PLoS Pathog. 2007;3:e2.
    doi: 10.1371/journal.ppat.0030002pmc: PMC1779298pubmed: 17238284google scholar: lookup
  61. Tsuda Y., Safronetz D., Brown K., Lacasse R., Marzi A., Ebihara H., Feldmann H.. Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the syrian hamster model of lethal Ebola virus infection. J. Infect. Dis. 2011;204((Suppl. 3)):S1090–S1097.
    doi: 10.1093/infdis/jir379pmc: PMC3189997pubmed: 21987746google scholar: lookup
  62. Marzi A., Hanley P.W., Haddock E., Martellaro C., Kobinger G., Feldmann H.. Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected with Ebola Virus Makona. J. Infect. Dis. 2016;214:S360–S366.
    doi: 10.1093/infdis/jiw218pmc: PMC5050468pubmed: 27496978google scholar: lookup
  63. Wong G., Audet J., Fernando L., Fausther-Bovendo H., Alimonti J.B., Kobinger G.P., Qiu X.. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine 2014;32:5722–5729.
    doi: 10.1016/j.vaccine.2014.08.028pmc: PMC7115511pubmed: 25173474google scholar: lookup
  64. Suder E., Furuyama W., Feldmann H., Marzi A., de Wit E.. The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials. Hum. Vaccines Immunother. 2018;14:2107–2113.
    doi: 10.1080/21645515.2018.1473698pmc: PMC6183239pubmed: 29757706google scholar: lookup
  65. Wolf J., Jannat R., Dubey S., Troth S., Onorato M.T., Coller B.A., Hanson M.E., Simon J.K.. Development of pandemic vaccines: ERVEBO case study. Vaccines 2021;9:190.
    doi: 10.3390/vaccines9030190pmc: PMC7996233pubmed: 33668698google scholar: lookup
  66. Huttner A., Dayer J.A., Yerly S., Combescure C., Auderset F., Desmeules J., Eickmann M., Finckh A., Goncalves A.R., Hooper J.W.. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: A randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect. Dis. 2015;15:1156–1166.
    doi: 10.1016/S1473-3099(15)00154-1pmc: PMC6624136pubmed: 26248510google scholar: lookup
  67. Agnandji S.T., Huttner A., Zinser M.E., Njuguna P., Dahlke C., Fernandes J.F., Yerly S., Dayer J.-A., Kraehling V., Kasonta R.. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. N. Engl. J. Med. 2016;374:1647–1660.
    doi: 10.1056/NEJMoa1502924pmc: PMC5490784pubmed: 25830326google scholar: lookup
  68. Regules J.A., Beigel J.H., Paolino K.M., Voell J., Castellano A.R., Hu Z., Muñoz P., Moon J.E., Ruck R.C., Bennett J.W.. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. N. Engl. J. Med. 2017;376:330–341.
    doi: 10.1056/NEJMoa1414216pmc: PMC5408576pubmed: 25830322google scholar: lookup
  69. ElSherif M.S., Brown C., Mackinnon-Cameron D., Li L., Racine T., Alimonti J., Rudge T.L., Sabourin C., Silvera P., Hooper J.W.. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: A randomized clinical trial. CMAJ 2017;189:E819–E827.
    doi: 10.1503/cmaj.170074pmc: PMC5478408pubmed: 28630358google scholar: lookup
  70. Dahlke C., Kasonta R., Lunemann S., Krähling V., Zinser M.E., Biedenkopf N., Fehling S.K., Ly M.L., Rechtien A., Stubbe H.C.. Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization. EBioMedicine 2017;19:107–118.
    doi: 10.1016/j.ebiom.2017.03.045pmc: PMC5440606pubmed: 28434944google scholar: lookup
  71. Heppner D.G., Kemp T.L., Martin B.K., Ramsey W.J., Nichols R., Dasen E.J., Link C., Das R., Xu Z.J., Sheldon E.A.. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: A phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect. Dis. 2017;17:854–866.
    doi: 10.1016/S1473-3099(17)30313-4pubmed: 28606591google scholar: lookup
  72. Juan-Giner A., Tchaton M., Jemmy J.P., Soumah A., Boum Y., Faga E.M., Cisse M., Grais R.F.. Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea. Vaccine 2019;37:7171–7177.
    doi: 10.1016/j.vaccine.2018.09.009pubmed: 30266489google scholar: lookup
  73. Agnandji S.T., Fernandes J.F., Bache E.B., Obiang Mba R.M., Brosnahan J.S., Kabwende L., Pitzinger P., Staarink P., Massinga-Loembe M., Krähling V.. Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial. PLoS Med. 2017;14:e1002402.
    doi: 10.1371/journal.pmed.1002402pmc: PMC5630143pubmed: 28985239google scholar: lookup
  74. Poetsch J.H., Dahlke C., Zinser M.E., Kasonta R., Lunemann S., Rechtien A., Ly M.L., Stubbe H.C., Krähling V., Biedenkopf N.. Detectable Vesicular Stomatitis Virus (VSV)-Specific Humoral and Cellular Immune Responses Following VSV-Ebola Virus Vaccination in Humans. J. Infect. Dis. 2019;219:556–561.
    doi: 10.1093/infdis/jiy565pmc: PMC6350948pubmed: 30452666google scholar: lookup
  75. Henao-Restrepo A.M., Camacho A., Longini I.M., Watson C.H., Edmunds W.J., Egger M., Carroll M.W., Dean N.E., Diatta I., Doumbia M.. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet 2017;389:505–518.
    doi: 10.1016/S0140-6736(16)32621-6pmc: PMC5364328pubmed: 28017403google scholar: lookup
  76. Widdowson M.A., Schrag S.J., Carter R.J., Carr W., Legardy-Williams J., Gibson L., Lisk D.R., Jalloh M.I., Bash-Taqi D.A., Kargbo S.A.S.. Implementing an Ebola Vaccine Study—Sierra Leone. MMWR Suppl. 2016;65:98–106.
    doi: 10.15585/mmwr.s攃a14pubmed: 27387395google scholar: lookup
  77. Halperin S.A., Arribas J.R., Rupp R., Andrews C.P., Chu L., Das R., Simon J.K., Onorato M.T., Liu K., Martin J.. Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults. J. Infect. Dis. 2017;215:1789–1798.
    doi: 10.1093/infdis/jix189pmc: PMC5853326pubmed: 28549145google scholar: lookup
  78. Sikakulya F.K., Mulisya O., Munyambalu D.K., Bunduki G.K.. Ebola in the Eastern Democratic Republic of Congo: One Health approach to infectious disease control. One Health 2020;9:100117.
    doi: 10.1016/j.onehlt.2019.100117pmc: PMC6976930pubmed: 31993475google scholar: lookup
  79. Wells C.R., Pandey A., Parpia A.S., Fitzpatrick M.C., Meyers L.A., Singer B.H., Galvani A.P.. Ebola vaccination in the Democratic Republic of the Congo. Proc. Natl. Acad. Sci. USA 2019;116:10178–10183.
    doi: 10.1073/pnas.1817329116pmc: PMC6525480pubmed: 31036657google scholar: lookup
  80. Ollmann Saphire E.. A Vaccine against Ebola Virus. Cell 2020;181:6.
    doi: 10.1016/j.cell.2020.03.011pubmed: 32243796google scholar: lookup
  81. Khurana S., Fuentes S., Coyle E.M., Ravichandran S., Davey R.T., Beigel J.H.. Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. Nat. Med. 2016;22:1439–1447.
    doi: 10.1038/nm.4201pubmed: 27798615google scholar: lookup
  82. Ehrhardt S.A., Zehner M., Krähling V., Cohen-Dvashi H., Kreer C., Elad N., Gruell H., Ercanoglu M.S., Schommers P., Gieselmann L.. Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. Nat. Med. 2019;25:1589–1600.
    doi: 10.1038/s41591-019-0602-4pubmed: 31591605google scholar: lookup
  83. Geisbert T.W., Daddario-DiCaprio K.M., Lewis M.G., Geisbert J.B., Grolla A., Leung A., Paragas J., Matthias L., Smith M.A., Jones S.M.. Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008;4:e1000225.
    doi: 10.1371/journal.ppat.1000225pmc: PMC2582959pubmed: 19043556google scholar: lookup
  84. Marzi A., Engelmann F., Feldmann F., Haberthur K., Shupert W.L., Brining D., Scott D.P., Geisbert T.W., Kawaoka Y., Katze M.G.. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc. Natl. Acad. Sci. USA 2013;110:1893–1898.
    doi: 10.1073/pnas.1209591110pmc: PMC3562844pubmed: 23319647google scholar: lookup
  85. Farooq F., Beck K., Paolino K.M., Phillips R., Waters N.C., Regules J.A., Bergmann-Leitner E.S.. Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine. Sci. Rep. 2016;6:27944.
    doi: 10.1038/srep27944pmc: PMC4914957pubmed: 27323685google scholar: lookup
  86. Sakabe S., Sullivan B.M., Hartnett J.N., Robles-Sikisaka R., Gangavarapu K., Cubitt B., Ware B.C., Kotliar D., Branco L.M., Goba A.. Analysis of CD8+ T cell response during the 2013–2016 Ebola epidemic in West Africa. Proc. Natl. Acad. Sci. USA 2018;115:E7578–E7586.
    doi: 10.1073/pnas.1806200115pmc: PMC6094108pubmed: 30038008google scholar: lookup
  87. Warfield K.L., Perkins J.G., Swenson D.L., Deal E.M., Bosio C.M., Aman M.J., Yokoyama W.M., Young H.A., Bavari S.. Role of natural killer cells innate protection against lethal Ebola virus infection. J. Exp. Med. 2004;200:169–179.
    doi: 10.1084/jem.20032141pmc: PMC2212007pubmed: 15249592google scholar: lookup
  88. Marzi A., Robertson S.J., Haddock E., Feldmann F., Hanley P.W., Scott D.P., Strong J.E., Kobinger G., Best S.M., Feldmann H.. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science 2015;349:739–742.
    doi: 10.1126/science.aab3920pmc: PMC11040598pubmed: 26249231google scholar: lookup
  89. Menicucci A.R., Jankeel A., Feldmann H., Marzi A., Messaoudi I.. Antiviral innate responses induced by VSV-EBOV vaccination contribute to rapid protection. mBio 2019;10:e00597-19.
    doi: 10.1128/mBio.00597-19pmc: PMC6538780pubmed: 31138743google scholar: lookup
  90. Roberts A., Buonocore L., Price R., Forman J., Rose J.K.. Attenuated Vesicular Stomatitis Viruses as Vaccine Vectors. J. Virol. 1999;73:3723–3732.
    doi: 10.1128/JVI.73.5.3723-3732.1999pmc: PMC104148pubmed: 10196265google scholar: lookup
  91. Marzi A., Feldmann F., Geisbert T.W., Feldmann H., Safronetz D.. Vesicular stomatitis virus–based vaccines against lassa and ebola viruses. Emerg. Infect. Dis. 2015;21:305–307.
    doi: 10.3201/eid2102.141649pmc: PMC4313664pubmed: 25625358google scholar: lookup
  92. Hastie E., Cataldi M., Marriott I., Grdzelishvili V.Z.. Understanding and altering cell tropism of vesicular stomatitis virus. Virus Res. 2013;176:16–32.
    doi: 10.1016/j.virusres.2013.06.003pmc: PMC3865924pubmed: 23796410google scholar: lookup
  93. Mire C.E., Miller A.D., Carville A., Westmoreland S.V., Geisbert J.B., Mansfield K.G., Feldmann H., Hensley L.E., Geisbert T.W.. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl. Trop. Dis. 2012;6:e1567.
    doi: 10.1371/journal.pntd.0001567pmc: PMC3308941pubmed: 22448291google scholar: lookup
  94. McWilliams I.L., Kielczewski J.L., Ireland D.D.C., Sykes J.S., Lewkowicz A.P., Konduru K., Xu B.C., Chan C.C., Caspi R.R., Manangeeswaran M.. Pseudovirus rVSVΔG-ZEBOV-GP Infects Neurons in Retina and CNS, Causing Apoptosis and Neurodegeneration in Neonatal Mice. Cell Rep. 2019;26:1718–1726.e4.
    doi: 10.1016/j.celrep.2019.01.069pmc: PMC6748882pubmed: 30759384google scholar: lookup
  95. De Wit E., Marzi A., Bushmaker T., Brining D., Scott D., Richt J.A., Geisbert T.W., Feldmann H.. Safety of recombinant VSV-Ebola virus vaccine vector in pigs. Emerg. Infect. Dis. 2015;21:702–704.
    doi: 10.3201/eid2104.142012pmc: PMC4378486pubmed: 25811738google scholar: lookup
  96. Morozov I., Monath T.P., Meekins D.A., Trujillo J.D., Sunwoo S.Y., Urbaniak K., Kim I.J., Narayanan S.K., Indran S.V., Ma W.. High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission. Emerg. Microbes Infect. 2021;10:651–663.
    doi: 10.1080/22221751.2021.1903343pmc: PMC8023602pubmed: 33719915google scholar: lookup
  97. Daddario-DiCaprio K.M., Geisbert T.W., Geisbert J.B., Ströher U., Hensley L.E., Grolla A., Fritz E.A., Feldmann F., Feldmann H., Jones S.M.. Cross-Protection against Marburg Virus Strains by Using a Live, Attenuated Recombinant Vaccine. J. Virol. 2006;80:9659–9666.
    doi: 10.1128/JVI.00959-06pmc: PMC1617222pubmed: 16973570google scholar: lookup
  98. Mire C.E., Geisbert J.B., Agans K.N., Satterfield B.A., Versteeg K.M., Fritz E.A., Feldmann H., Hensley L.E., Geisbert T.W.. Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. PLoS ONE 2014;9:e94355.
    doi: 10.1371/journal.pone.0094355pmc: PMC3997383pubmed: 24759889google scholar: lookup
  99. Daddario-DiCaprio K.M., Geisbert T.W., Ströher U., Geisbert J.B., Grolla A., Fritz E.A., Fernando L., Kagan E., Jahrling P.B., Hensley L.E.. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: An efficacy assessment. Lancet 2006;367:1399–1404.
    doi: 10.1016/S0140-6736(06)68546-2pubmed: 16650649google scholar: lookup
  100. Geisbert T.W., Hensley L.E., Geisbert J.B., Leung A., Johnson J.C., Grolla A., Feldmann H.. Postexposure treatment of marburg virus infection. Emerg. Infect. Dis. 2010;16:1119–1122.
    doi: 10.3201/eid1607.100159pmc: PMC3321919pubmed: 20587184google scholar: lookup
  101. Woolsey C., Geisbert J.B., Matassov D., Agans K.N., Borisevich V., Cross R.W., Deer D.J., Fenton K.A., Eldridge J.H., Mire C.E.. Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates. J. Infect. Dis. 2018;218:S582–S587.
    doi: 10.1093/infdis/jiy293pmc: PMC6249565pubmed: 29939296google scholar: lookup
  102. Marzi A., Menicucci A.R., Engelmann F., Callison J., Horne E.J., Feldmann F., Jankeel A., Feldmann H., Messaoudi I.. Protection against marburg virus using a recombinant VSV-vaccine depends on T and B cell activation. Front. Immunol. 2019;9:3071.
    doi: 10.3389/fimmu.2018.03071pmc: PMC6350103pubmed: 30723475google scholar: lookup
  103. Woolsey C., Jankeel A., Matassov D., Geisbert J.B., Agans K.N., Borisevich V., Cross R.W., Deer D.J., Fenton K.A., Latham T.E.. Immune correlates of postexposure vaccine protection against Marburg virus. Sci. Rep. 2020;10:3071.
    doi: 10.1038/s41598-020-59976-3pmc: PMC7033120pubmed: 32080323google scholar: lookup
  104. Mire C.E., Geisbert J.B., Marzi A., Agans K.N., Feldmann H., Geisbert T.W.. Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus. PLoS Negl. Trop. Dis. 2013;7:e2600.
    doi: 10.1371/journal.pntd.0002600pmc: PMC3868506pubmed: 24367715google scholar: lookup
  105. Geisbert T.W., Daddario-DiCaprio K.M., Williams K.J.N., Geisbert J.B., Leung A., Feldmann F., Hensley L.E., Feldmann H., Jones S.M.. Recombinant Vesicular Stomatitis Virus Vector Mediates Postexposure Protection against Sudan Ebola Hemorrhagic Fever in Nonhuman Primates. J. Virol. 2008;82:5664–5668.
    doi: 10.1128/JVI.00456-08pmc: PMC2395203pubmed: 18385248google scholar: lookup
  106. Falzarano D., Feldmann F., Grolla A., Leung A., Ebihara H., Strong J.E., Marzi A., Takada A., Jones S., Gren J.. Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. J. Infect. Dis. 2011;204((Suppl. 3)):S1082–S1089.
    doi: 10.1093/infdis/jir350pmc: PMC3189995pubmed: 21987745google scholar: lookup
  107. Marzi A., Ebihara H., Callison J., Groseth A., Williams K.J., Geisbert T.W., Feldmann H.. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J. Infect. Dis. 2011;204((Suppl. 3)):S1066–S1074.
    doi: 10.1093/infdis/jir348pmc: PMC3203393pubmed: 21987743google scholar: lookup
  108. Geisbert T.W., Geisbert J.B., Leung A., Daddario-DiCaprio K.M., Hensley L.E., Grolla A., Feldmann H.. Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola Virus. J. Virol. 2009;83:7296–7304.
    doi: 10.1128/JVI.00561-09pmc: PMC2704787pubmed: 19386702google scholar: lookup
  109. Cross R.W., Xu R., Matassov D., Hamm S., Latham T.E., Gerardi C.S., Nowak R.M., Geisbert J.B., Ota-Setlik A., Agans K.N.. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. J. Clin. Investig. 2020;130:539–551.
    doi: 10.1172/JCI131958pmc: PMC6934204pubmed: 31820871google scholar: lookup
  110. Matassov D., Mire C.E., Latham T., Geisbert J.B., Xu R., Ota-Setlik A., Agans K.N., Kobs D.J., Wendling M.Q.S., Burnaugh A.. Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge. J. Virol. 2018;92:e01190-17.
    doi: 10.1128/JVI.01190-17pmc: PMC5774882pubmed: 29142131google scholar: lookup
  111. Mire C.E., Geisbert J.B., Versteeg K.M., Mamaeva N., Agans K.N., Geisbert T.W., Connor J.H.. A Single-Vector, Single-Injection Trivalent Filovirus Vaccine: Proof of Concept Study in Outbred Guinea Pigs. J. Infect. Dis. 2015;212:S384–S388.
    doi: 10.1093/infdis/jiv126pmc: PMC4564539pubmed: 25957964google scholar: lookup
  112. Geisbert T.W., Jones S., Fritz E.A., Shurtleff A.C., Geisbert J.B., Liebscher R., Grolla A., Ströher U., Fernando L., Daddario K.M.. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2005;2:e183.
    doi: 10.1371/journal.pmed.0020183pmc: PMC1160587pubmed: 15971954google scholar: lookup
  113. Safronetz D., Mire C., Rosenke K., Feldmann F., Haddock E., Geisbert T., Feldmann H.. A Recombinant Vesicular Stomatitis Virus-Based Lassa Fever Vaccine Protects Guinea Pigs and Macaques against Challenge with Geographically and Genetically Distinct Lassa Viruses. PLoS Negl. Trop. Dis. 2015;9:e0003736.
    doi: 10.1371/journal.pntd.0003736pmc: PMC4401668pubmed: 25884628google scholar: lookup
  114. Stein D.R., Warner B.M., Soule G., Tierney K., Frost K.L., Booth S., Safronetz D.. A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs. npj Vaccines 2019;4:8.
    doi: 10.1038/s41541-019-0104-xpmc: PMC6368541pubmed: 30774999google scholar: lookup
  115. Stein D.R., Sroga P., Warner B.M., Deschambault Y., Poliquin G., Safronetz D.. Evaluating temperature sensitivity of vesicular stomatitis virus–based vaccines. Emerg. Infect. Dis. 2019;25:1563–1566.
    doi: 10.3201/eid2508.190281pmc: PMC6649338pubmed: 31141474google scholar: lookup
  116. Van den Pol A.N., Mao G., Chattopadhyay A., Rose J.K., Davis J.N.. Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain. J. Virol. 2017;91:e02154-16.
    doi: 10.1128/JVI.02154-16pmc: PMC5331823pubmed: 28077641google scholar: lookup
  117. Lo M.K., Bird B.H., Chattopadhyay A., Drew C.P., Martin B.E., Coleman J.D., Rose J.K., Nichol S.T., Spiropoulou C.F.. Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters. Antivir. Res. 2014;101:26–29.
    doi: 10.1016/j.antiviral.2013.10.012pmc: PMC3874889pubmed: 24184127google scholar: lookup
  118. Mire C.E., Versteeg K.M., Cross R.W., Agans K.N., Fenton K.A., Whitt M.A., Geisbert T.W.. Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease. Virol. J. 2013;10:353.
    doi: 10.1186/1743-422X-10-353pmc: PMC3878732pubmed: 24330654google scholar: lookup
  119. Debuysscher B.L., Scott D., Thomas T., Feldmann H., Prescott J.. Peri-exposure protection against Nipah virus disease using a single-dose recombinant vesicular stomatitis virus-based vaccine. npj Vaccines 2016;1:16002.
    doi: 10.1038/npjvaccines.2016.2pmc: PMC5505655pubmed: 28706736google scholar: lookup
  120. Prescott J., DeBuysscher B.L., Feldmann F., Gardner D.J., Haddock E., Martellaro C., Scott D., Feldmann H.. Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease. Vaccine 2015;33:2823–2829.
    doi: 10.1016/j.vaccine.2015.03.089pmc: PMC4433813pubmed: 25865472google scholar: lookup
  121. Mire C.E., Geisbert J.B., Agans K.N., Versteeg K.M., Deer D.J., Satterfield B.A., Fenton K.A., Geisbert T.W.. Use of single-injection recombinant vesicular stomatitis virus vaccine to protect nonhuman primates against lethal nipah virus disease. Emerg. Infect. Dis. 2019;25:1144–1152.
    doi: 10.3201/eid2506.181620pmc: PMC6537706pubmed: 31107231google scholar: lookup
  122. Kurup D., Wirblich C., Feldmann H., Marzi A., Schnell M.J.. Rhabdovirus-Based Vaccine Platforms against Henipaviruses. J. Virol. 2015;89:144–154.
    doi: 10.1128/JVI.02308-14pmc: PMC4301098pubmed: 25320306google scholar: lookup
  123. Kapadia S.U., Rose J.K., Lamirande E., Vogel L., Subbarao K., Roberts A.. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 2005;340:174–182.
    doi: 10.1016/j.virol.2005.06.016pmc: PMC7111745pubmed: 16043204google scholar: lookup
  124. Kapadia S.U., Simon I.D., Rose J.K.. SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector. Virology 2008;376:165–172.
    doi: 10.1016/j.virol.2008.03.002pmc: PMC7103385pubmed: 18396306google scholar: lookup
  125. Liu R., Wang J., Shao Y., Wang X., Zhang H., Shuai L., Ge J., Wen Z., Bu Z.. A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization. Antivir. Res. 2018;150:30–38.
    doi: 10.1016/j.antiviral.2017.12.007pmc: PMC7113862pubmed: 29246504google scholar: lookup
  126. Case J.B., Rothlauf P.W., Chen R.E., Kafai N.M., Fox J.M., Smith B.K., Shrihari S., McCune B.T., Harvey I.B., Keeler S.P.. Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice. Cell Host Microbe 2020;28:465–474.e4.
    doi: 10.1016/j.chom.2020.07.018pmc: PMC7391951pubmed: 32798445google scholar: lookup
  127. Hennrich A.A., Sawatsky B., Santos-Mandujano R., Banda D.H., Oberhuber M., Schopf A., Pfaffinger V., Wittwer K., Riedel C., Pfaller C.K.. Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: Protection of mice after a single immunization. PLoS Pathog. 2021;17:e1009064.
    doi: 10.1371/journal.ppat.1009064pmc: PMC8092985pubmed: 33882114google scholar: lookup
  128. Yahalom-Ronen Y., Tamir H., Melamed S., Politi B., Shifman O., Achdout H., Vitner E.B., Israeli O., Milrot E., Stein D.. A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge. Nat. Commun. 2020;11:6402.
    doi: 10.1038/s41467-020-20228-7pmc: PMC7745033pubmed: 33328475google scholar: lookup
  129. Furuyama W., Shifflett K., Pinski A.N., Griffin A.J., Feldmann F., Okumura A., Gourdine T., Jankeel A., Lovaglio J., Hanley P.W.. Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine. bioRxiv Prepr. Serv. Biol. 2021.
    doi: 10.1101/2021.01.19.426885pmc: PMC8749411pubmed: 35012339google scholar: lookup
  130. Emanuel J., Callison J., Dowd K.A., Pierson T.C., Feldmann H., Marzi A.. A VSV-based Zika virus vaccine protects mice from lethal challenge. Sci. Rep. 2018;8:11043.
    doi: 10.1038/s41598-018-29401-xpmc: PMC6056530pubmed: 30038228google scholar: lookup
  131. Li A., Yu J., Lu M., Ma Y., Attia Z., Shan C., Xue M., Liang X., Craig K., Makadiya N.. A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein. Nat. Commun. 2018;9:3067.
    doi: 10.1038/s41467-018-05276-4pmc: PMC6076265pubmed: 30076287google scholar: lookup
  132. Li A., Xue M., Attia Z., Yu J., Lu M., Shan C., Liang X., Gao T.Z., Shi P.-Y., Peeples M.E.. Vesicular Stomatitis Virus and DNA Vaccines Expressing Zika Virus Nonstructural Protein 1 Induce Substantial but Not Sterilizing Protection against Zika Virus Infection. J. Virol. 2020;94:e00048-20.
    doi: 10.1128/JVI.00048-20pmc: PMC7431813pubmed: 32554698google scholar: lookup
  133. Rodriguez S.E., Cross R.W., Fenton K.A., Bente D.A., Mire C.E., Geisbert T.W.. Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever. Sci. Rep. 2019;9:7755.
    doi: 10.1038/s41598-019-44210-6pmc: PMC6533279pubmed: 31123310google scholar: lookup
  134. Bishnoi S., Tiwari R., Gupta S., Byrareddy S.N., Nayak D.. Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in cancer therapy. Viruses 2018;10:90.
    doi: 10.3390/v10020090pmc: PMC5850397pubmed: 29473868google scholar: lookup

Citations

This article has been cited 41 times.
  1. Grewe I, Zoran T, Addo MM. Sex Differences in Response to Viral Vector Vaccines-Implications for Future Vaccine Design. Immunol Rev 2026 Mar;338(1):e70098.
    doi: 10.1111/imr.70098pubmed: 41612856google scholar: lookup
  2. Li J, Xiao Y, Li X, Dai Y. The role of ADAR1 in human pathophysiology. Front Cell Dev Biol 2025;13:1672970.
    doi: 10.3389/fcell.2025.1672970pubmed: 41488000google scholar: lookup
  3. Sun X, Zhang L, Chen G, Yang F, Ning X, Qiu J, Gao Y, Yang J, Zhang W, Zhang Z, Zhang Y, Li S, Zeng M, Fu B, Li Y, Peng C, Li W. A cocktail vaccine with monkeypox virus antigens confers protection without selecting mutations in potential immune evasion genes in the vaccinia WR strain challenge. mBio 2026 Feb 11;17(2):e0320025.
    doi: 10.1128/mbio.03200-25pubmed: 41474326google scholar: lookup
  4. Jeon H, Lee C. The Dual Role of A20 (TNFAIP3) in Viral Infection: A Context-Dependent Regulator of Immunity and Pathogenesis. Viruses 2025 Dec 17;17(12).
    doi: 10.3390/v17121634pubmed: 41472303google scholar: lookup
  5. Tian T, Ma L, Mao L, Wang X, Cheng L, Ma Q, Xu R, Zhou G. Mechanism of action of over-expressing NY-ESO-1 in vesicular stomatitis virus and its combination therapy with NY-ESO-1 TCR-T. Front Immunol 2025;16:1617941.
    doi: 10.3389/fimmu.2025.1617941pubmed: 40873562google scholar: lookup
  6. Chang M, Huang H, Yue M, Jiang Y, Yan S, Chen Y, Wu W, Gao Y, Fang M, Yuan Q, Xiong H, Zhang T. Development of COVID-19 Vaccine Candidates Using Attenuated Recombinant Vesicular Stomatitis Virus Vectors with M Protein Mutations. Viruses 2025 Jul 30;17(8).
    doi: 10.3390/v17081062pubmed: 40872776google scholar: lookup
  7. Ramos-Cela M, Forconi V, Antonelli R, Manenti A, Montomoli E. Exploring the Use of Viral Vectors Pseudotyped with Viral Glycoproteins as Tools to Study Antibody-Mediated Neutralizing Activity. Microorganisms 2025 Jul 31;13(8).
    doi: 10.3390/microorganisms13081785pubmed: 40871289google scholar: lookup
  8. Sownthirarajan B, Mason M, Loganathan G, Manivasagam S, Jangra RK, Tan GS, Perez DR, Manicassamy B. A versatile H5N1-VSV platform for safe influenza virus research applications. J Virol 2025 Sep 23;99(9):e0097525.
    doi: 10.1128/jvi.00975-25pubmed: 40778766google scholar: lookup
  9. Guo L, McFadden E, Slough MM, Stone ET, Berrigan J, Mittler E, Hatzakis K, Hinkley T, Kain HS, Ke Z, Warner NL, Erasmus JH, Chandran K, McLellan JS. High-resolution in situ structures of hantavirus glycoprotein tetramers. bioRxiv 2025 Jun 18;.
    doi: 10.1101/2025.06.17.660152pubmed: 40667040google scholar: lookup
  10. Otręba M, Marek Ł, Stojko J, Rzepecka-Stojko A. Bee products as alternatives in the treatment of viral infections. J Sci Food Agric 2026 Jan 15;106(1):33-54.
    doi: 10.1002/jsfa.70017pubmed: 40613476google scholar: lookup
  11. Park PG, Lee SY, Youn H, Hong KJ. Promising Vaccine Formulations for Emerging Infectious Diseases. Int J Mol Sci 2025 May 20;26(10).
    doi: 10.3390/ijms26104893pubmed: 40430032google scholar: lookup
  12. Cavalcante MSB, Santos DS, Araújo LM, Freitas PL, Silva CAM, Carvalho KGB, Araújo MTF, da Silva EVP, Rodrigues de Farias APD, Guerreiro Diniz D, Picanço Diniz CW, Diniz JAP. Inflammatory and neuropathological responses to Vesiculovirus carajas encephalitis in adult mice: variability, tolerance and resistance. Front Cell Infect Microbiol 2025;15:1499658.
    doi: 10.3389/fcimb.2025.1499658pubmed: 40078875google scholar: lookup
  13. Rex EA, Seo D, Embry A, Arulanandam R, Spinelli MM, Diallo JS, Gammon DB. Activation and Evasion of the FEAR Pathway by RNA Viruses. bioRxiv 2025 Feb 25;.
    doi: 10.1101/2024.08.22.609092pubmed: 40060670google scholar: lookup
  14. Hildt E. [Platform technologies in vaccine development]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2025 Apr;68(4):368-377.
    doi: 10.1007/s00103-025-04024-6pubmed: 40035793google scholar: lookup
  15. Ahmed MM, Okesanya OJ, Ukoaka BM, Ibrahim AM, Lucero-Prisno DE 3rd. Vesicular Stomatitis Virus: Insights into Pathogenesis, Immune Evasion, and Technological Innovations in Oncolytic and Vaccine Development. Viruses 2024 Dec 18;16(12).
    doi: 10.3390/v16121933pubmed: 39772239google scholar: lookup
  16. Richards PT, Briseño JAA, Brunton BA, Maury W. In Vivo Investigation of Filovirus Glycoprotein-Mediated Infection in a BSL2 Setting. Methods Mol Biol 2025;2877:183-198.
    doi: 10.1007/978-1-0716-4256-6_13pubmed: 39585622google scholar: lookup
  17. Moles CM, Basu R, Weijmarshausen P, Ho B, Farhat M, Flaat T, Smith BF. Leveraging Synthetic Virology for the Rapid Engineering of Vesicular Stomatitis Virus (VSV). Viruses 2024 Oct 21;16(10).
    doi: 10.3390/v16101641pubmed: 39459973google scholar: lookup
  18. Hofer T, Pipperger L, Danklmaier S, Das K, Wollmann G. Characterization of the Anti-Viral and Vaccine-Specific CD8(+) T Cell Composition upon Treatment with the Cancer Vaccine VSV-GP. Vaccines (Basel) 2024 Aug 1;12(8).
    doi: 10.3390/vaccines12080867pubmed: 39203993google scholar: lookup
  19. Krause TB, Cepko CL. Abortive and productive infection of CNS cell types following in vivo delivery of VSV. Proc Natl Acad Sci U S A 2024 Aug 27;121(35):e2406421121.
    doi: 10.1073/pnas.2406421121pubmed: 39159381google scholar: lookup
  20. Hodel KVS, Fiuza BSD, Conceição RS, Aleluia ACM, Pitanga TN, Fonseca LMDS, Valente CO, Minafra-Rezende CS, Machado BAS. Pharmacovigilance in Vaccines: Importance, Main Aspects, Perspectives, and Challenges-A Narrative Review. Pharmaceuticals (Basel) 2024 Jun 19;17(6).
    doi: 10.3390/ph17060807pubmed: 38931474google scholar: lookup
  21. Marqués MC, Andreu-Moreno I, Sanjuán R, Elena SF, Geller R. An efficient plasmid-based system for the recovery of recombinant vesicular stomatitis virus encoding foreign glycoproteins. Sci Rep 2024 Jun 25;14(1):14644.
    doi: 10.1038/s41598-024-65384-8pubmed: 38918479google scholar: lookup
  22. Cornetta K, Lin TY, Tao H, Huang J, Piskorowski J, Wilcox P, Xie D, Yao J, House K, Nance E, Duffy L. Product Enhanced Reverse Transcriptase for assessing replication competent virus in vectors retroviral vectors pseudotyped with GALV and VSV-G envelopes. J Virol Methods 2024 Sep;329:114988.
    doi: 10.1016/j.jviromet.2024.114988pubmed: 38908550google scholar: lookup
  23. Wang Q, Wang S, Shi Z, Li Z, Zhao Y, Feng N, Wang T, Yan F, Xia X. Establishment of two serological methods for detecting IgG and neutralizing antibodies against Crimean-Congo hemorrhagic fever virus glycoprotein. Front Cell Infect Microbiol 2024;14:1341332.
    doi: 10.3389/fcimb.2024.1341332pubmed: 38746783google scholar: lookup
  24. Salawudeen A, Soule G, Tailor N, Klassen L, Audet J, Sloan A, Deschambault Y, Safronetz D. Protective Efficacy of Lyophilized Vesicular Stomatitis Virus-Based Vaccines in Animal Model. Emerg Infect Dis 2024 May;30(5):1004-1008.
    doi: 10.3201/eid3005.231248pubmed: 38666640google scholar: lookup
  25. Park SJ, Park H, Back SM, Lee YJ, Seo JW, Kim D, Lee JH, Kwak C, Han KH, Son HY, Kim YB. Genotoxicity and safety pharmacology of the rVSVInd(GML)-mspSGtc vaccine against SARS-CoV-2 in Sprague-Dawley rats and Beagle dogs. Arch Toxicol 2024 Jul;98(7):2185-2197.
    doi: 10.1007/s00204-024-03746-xpubmed: 38607375google scholar: lookup
  26. Whelpley MJ, Zhou LH, Rascon J, Payne B, Moehn B, Young KI, Mire CE, Peters DPC, Rodriguez LL, Hanley KA. Community composition of black flies during and after the 2020 vesicular stomatitis virus outbreak in Southern New Mexico, USA. Parasit Vectors 2024 Feb 27;17(1):93.
    doi: 10.1186/s13071-024-06127-6pubmed: 38414030google scholar: lookup
  27. Marceau J, Safronetz D, Martellaro C, Marzi A, Rosenke K, Feldmann H. Bivalent VSV Vectors Mediate Rapid and Potent Protection from Andes Virus Challenge in Hamsters. Viruses 2024 Feb 11;16(2).
    doi: 10.3390/v16020279pubmed: 38400054google scholar: lookup
  28. King CR, Berezin CT, Peccoud J. Stochastic model of vesicular stomatitis virus replication reveals mutational effects on virion production. PLoS Comput Biol 2024 Feb;20(2):e1011373.
    doi: 10.1371/journal.pcbi.1011373pubmed: 38324583google scholar: lookup
  29. Wyżewski Z, Stępkowska J, Kobylińska AM, Mielcarska A, Mielcarska MB. Mcl-1 Protein and Viral Infections: A Narrative Review. Int J Mol Sci 2024 Jan 17;25(2).
    doi: 10.3390/ijms25021138pubmed: 38256213google scholar: lookup
  30. Han W, Fei X, Yang F, Sun X, Yang J, Qiu J, Zhang L, Zhang W, Chen G, Han W, He X, Liu Y, Li W. Transcriptome analysis of long non-coding RNA and mRNA Profiles in VSV-infected BHK-21 Cells. BMC Genomics 2024 Jan 15;25(1):62.
    doi: 10.1186/s12864-024-09991-9pubmed: 38225547google scholar: lookup
  31. Goad DW, Nesmelova AY, Yohe LR, Grdzelishvili VZ. Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells. J Virol 2023 Sep 28;97(9):e0100523.
    doi: 10.1128/jvi.01005-23pubmed: 37671865google scholar: lookup
  32. Cao W, He S, Liu G, Schulz H, Emeterio K, Chan M, Tierney K, Azaransky K, Soule G, Tailor N, Salawudeen A, Nichols R, Fusco J, Safronetz D, Banadyga L. The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigs. NPJ Vaccines 2023 Jun 10;8(1):91.
    doi: 10.1038/s41541-023-00685-zpubmed: 37301890google scholar: lookup
  33. Wawra S, Kessler S, Egel A, Solzin J, Burkert O, Hochdorfer D. Hydrodynamic characterization of a vesicular stomatitis virus-based oncolytic virus using analytical ultracentrifugation. Eur Biophys J 2023 Jul;52(4-5):379-386.
    doi: 10.1007/s00249-023-01649-wpubmed: 37133524google scholar: lookup
  34. Zhao Z, Wang B, Wu S, Zhang Z, Chen Y, Zhang J, Wang Y, Zhu D, Li Y, Xu J, Hou L, Chen W. Regulated control of virus replication by 4-hydroxytamoxifen-induced splicing. Front Microbiol 2023;14:1112580.
    doi: 10.3389/fmicb.2023.1112580pubmed: 36992923google scholar: lookup
  35. Saito T, Reyna RA, Taniguchi S, Littlefield K, Paessler S, Maruyama J. Vaccine Candidates against Arenavirus Infections. Vaccines (Basel) 2023 Mar 13;11(3).
    doi: 10.3390/vaccines11030635pubmed: 36992218google scholar: lookup
  36. Parham KA, Kim GN, Richer CG, Ninkov M, Wu K, Saeedian N, Li Y, Rashu R, Barr SD, Arts EJ, Haeryfar SMM, Kang CY, Troyer RM. Monovalent and trivalent VSV-based COVID-19 vaccines elicit neutralizing antibodies and CD8(+) T cells against SARS-CoV-2 variants. iScience 2023 Apr 21;26(4):106292.
    doi: 10.1016/j.isci.2023.106292pubmed: 36915805google scholar: lookup
  37. Vijver SV, Danklmaier S, Pipperger L, Gronauer R, Floriani G, Hackl H, Das K, Wollmann G. Prediction and validation of murine MHC class I epitopes of the recombinant virus VSV-GP. Front Immunol 2022;13:1100730.
    doi: 10.3389/fimmu.2022.1100730pubmed: 36741416google scholar: lookup
  38. Hu H, Xia Q, Hu J, Wang S. Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects. J Clin Med 2022 Nov 26;11(23).
    doi: 10.3390/jcm11236997pubmed: 36498574google scholar: lookup
  39. Zhu W, Liu G, Cao W, He S, Leung A, Ströher U, Fairchild MJ, Nichols R, Crowell J, Fusco J, Banadyga L. A Cloned Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine, PHV01, Protects Guinea Pigs from Lethal Marburg Virus Disease. Vaccines (Basel) 2022 Jun 23;10(7).
    doi: 10.3390/vaccines10071004pubmed: 35891170google scholar: lookup
  40. Travieso T, Li J, Mahesh S, Mello JDFRE, Blasi M. The use of viral vectors in vaccine development. NPJ Vaccines 2022 Jul 4;7(1):75.
    doi: 10.1038/s41541-022-00503-ypubmed: 35787629google scholar: lookup
  41. Cabot M, Kiessling V, White JM, Tamm LK. Endosomes supporting fusion mediated by vesicular stomatitis virus glycoprotein have distinctive motion and acidification. Traffic 2022 Apr;23(4):221-234.
    doi: 10.1111/tra.12836pubmed: 35147273google scholar: lookup
Subscribe to our newsletter
Join 99,911 horse owners like you who receive our email updates on horse health and nutrition.